Halozyme Therapeutics Inc (HALO) — Cash Flow Quality Index
Halozyme Therapeutics Inc (HALO) has a Cash Flow Quality Index of 1.02x as of September 2025. Operating cash flow of $178.60 Million exceeds net income of $175.22 Million, indicating high earnings quality where cash backs reported profits. Explore Halozyme Therapeutics Inc (HALO) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Halozyme Therapeutics Inc Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Halozyme Therapeutics Inc across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check HALO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Halozyme Therapeutics Inc (2017–2024)
Year-by-year earnings quality comparison for Halozyme Therapeutics Inc. For live market cap and the full company financial profile, see market value of Halozyme Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.08x | $479.06 Million | $444.09 Million | ▼ -21.8% |
| 2023 | 1.38x | $388.57 Million | $281.59 Million | ▲ +16.2% |
| 2022 | 1.19x | $240.11 Million | $202.13 Million | ▲ +59.8% |
| 2021 | 0.74x | $299.44 Million | $402.71 Million | ▲ +73.1% |
| 2020 | 0.43x | $55.45 Million | $129.09 Million | ▼ -79.8% |
| 2017 | 2.13x | $134.05 Million | $62.97 Million | — |